Sat. Oct 12th, 2024

The Houstonian Review

Reviewing Only The Best of Houston

Biopharma co. CNS Pharmaceuticals highlights European expansion in Q3 results

1 min read

CNS Pharmaceuticals has continued expanding its proposed clinical trials into Europe, after it acquired the rights to Berubicin in 2021.

Leave a Reply

Your email address will not be published.

Generated by Feedzy